Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma

Tejas Sankar, Zografos Caramanos, Rachid Assina, Jean Guy Villemure, Richard Leblanc, Adrian Langleben, Douglas L. Arnold, Mark C. Preul

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Objective: Early prediction of imminent failure during chemotherapy for malignant glioma has the potential to guide proactive alterations in treatment before frank tumor progression. We prospectively followed patients with recurrent malignant glioma receiving tamoxifen chemotherapy using proton magnetic resonance spectroscopic imaging (1H-MRSI) to identify intratumoral metabolic changes preceding clinical and radiological failure. Methods: We performed serial 1H-MRSI examinations to assess intratumoral metabolite intensities in 16 patients receiving high-dose oral tamoxifen monotherapy for recurrent malignant glioma (WHO grade III or IV) as part of a phase II clinical trial. Patients were followed until treatment failure, death, or trial termination. Results: Patients were officially classified as responders (7 patients) or non-responders (9 patients) 8 weeks into treatment. At 8 weeks, responders and non-responders had different intratumoral intensities across all measured metabolites except choline. Beyond 8 weeks, metabolite intensities remained stable in all responders, but changed again with approaching disease progression. Choline, lipid, choline/NAA, and lactate/NAA were significantly elevated (P < 0.02), while creatine (P < 0.04) was significantly reduced, compared to stabilized levels on average 4 weeks prior to failure. Lactate was significantly elevated (P = 0.036) fully 8 weeks prior to failure. In one patient who was still responding to tamoxifen at the conclusion of the trial, metabolite intensities never deviated from 8-week levels for the duration of follow-up. Conclusions: Characteristic global intratumoral metabolic changes, detectable on serial 1H-MRSI studies, occur in response to chemotherapy for malignant glioma and may predict imminent treatment failure before actual clinical and radiological disease progression.

Original languageEnglish (US)
Pages (from-to)63-76
Number of pages14
JournalJournal of neuro-oncology
Issue number1
StatePublished - 2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neurology
  • Oncology
  • Cancer Research


  • Brain neoplasm
  • Chemotherapy
  • Glioma
  • Magnetic resonance imaging
  • Magnetic resonance spectroscopy
  • Tamoxifen


Dive into the research topics of 'Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma'. Together they form a unique fingerprint.

Cite this